Nuvo Pharmaceuticals (OTCMKTS:NRIFF) is scheduled to be releasing its earnings data before the market opens on Wednesday, August 14th.
Nuvo Pharmaceuticals (OTCMKTS:NRIFF) last announced its earnings results on Tuesday, May 14th. The company reported ($0.15) EPS for the quarter. Nuvo Pharmaceuticals had a negative net margin of 44.15% and a negative return on equity of 21.93%. The business had revenue of $10.94 million for the quarter.
Shares of NRIFF stock opened at $0.48 on Tuesday. Nuvo Pharmaceuticals has a 12 month low of $0.45 and a 12 month high of $2.48. The company has a current ratio of 2.60, a quick ratio of 1.91 and a debt-to-equity ratio of 9.22. The firm’s fifty day simple moving average is $0.55.
About Nuvo Pharmaceuticals
Nuvo Pharmaceuticals Inc, a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair.
Further Reading: Find a Trading Strategy That Works
Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.